Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4(+) T cells to reduce the latent HIV(+) cell reservoir

Chimeric Antigen Receptor (CAR)-redirected T cells show great efficacy in the patient-specific therapy of hematologic malignancies. Here, we demonstrate that a DARPin with specificity for CD4 specifically redirects and triggers the activation of CAR engineered T cells resulting in the depletion of C...

Descripción completa

Detalles Bibliográficos
Autores principales: Patasic, Lea, Seifried, Janna, Bezler, Valerie, Kaljanac, Marcell, Schneider, Irene C., Schmitz, Heike, Tondera, Christiane, Hartmann, Jessica, Hombach, Andreas, Buchholz, Christian J., Abken, Hinrich, König, Renate, Cichutek, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568711/
https://www.ncbi.nlm.nih.gov/pubmed/32918599
http://dx.doi.org/10.1007/s00430-020-00692-0
Descripción
Sumario:Chimeric Antigen Receptor (CAR)-redirected T cells show great efficacy in the patient-specific therapy of hematologic malignancies. Here, we demonstrate that a DARPin with specificity for CD4 specifically redirects and triggers the activation of CAR engineered T cells resulting in the depletion of CD4(+) target cells aiming for elimination of the human immunodeficiency virus (HIV) reservoir. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00430-020-00692-0) contains supplementary material, which is available to authorized users.

Ejemplares similares